Cochrane · systematic review · CD012102
Long‐acting inhaled bronchodilators for cystic fibrosis
Smith, S, Edwards, CT · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
7
No studies
4
Included studies
NR
No studies 4 · 36.4%Ungraded 0 · 0%Very low 1 · 9.1%Low 2 · 18.2%Moderate 3 · 27.3%High 1 · 9.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Beta‐2 agonists versus placebo
Population: adults and children with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1: change from baseline Beta‐2 agonists vs placebo | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Participant‐reported outcomes: quality of life (measured by CFQ‐R) Beta‐2 agonists vs placebo | no estimate extracted | NR | No studies |
Adverse events after tiotropium 5.0 µg Beta‐2 agonists vs placebo | no estimate extracted | NR | No studies |
Pulmonary exacerbations Beta‐2 agonists vs placebo | no estimate extracted | NR | No studies |
Other measures of lung function Beta‐2 agonists vs placebo | no estimate extracted | NR | No studies |
LAMAs versus placebo
Population: adults and children with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1: mean change from baseline (L) LAMAs vs placebo | no estimate extracted | 1 study · 34 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Participant‐reported outcomes: quality of life (measured by CFQ‐R) LAMAs vs placebo | no estimate extracted | 2 studies · 974 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Adverse events after tiotropium 5.0 µg LAMAs vs placebo | RR 0.96 [0.88, 1.04] | 2 studies · 807 participants | High |
Pulmonary exacerbations: participants reporting ≥1 pulmonary exacerbation during the trial period after tiotropium 5 µg LAMAs vs placebo | RR 0.6 [0.32, 1.12] | 2 studies · 805 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Other measures of lung function: mean change from baseline in FEV1 AUC0-4h (% predicted) after tiotropium 5.0 µg LAMAs vs placebo | no estimate extracted | 2 studies · 770 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Other measures of lung function: mean change from baseline in trough FEV1 (% predicted) after tiotropium 5.0 µg LAMAs vs placebo | no estimate extracted | 2 studies · 772 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |